Fractyl Health (GUTS) Eyes $1.00 Compliance Target (+23% Upside Potential)

Key Takeaways

• The $1.00 figure here serves as a fallback objective tied to a Nasdaq listing rule, rather than reflecting an analyst price-target consensus.
• A 1-for-12 reverse stock split in October 2026 rendered most published analyst targets outdated, so this analysis uses the widely discussed $1.00 milestone instead of any aggregate of analyst targets.
• At a closing price of $0.81 on November 10, 2026, reaching $1.00 would require a rise of roughly 23%.
• The strongest support comes from clinical results: the REMAIN-1 pivotal study met its co-primary endpoint in October 2026, and the company is restructuring to focus on its Revita program.
• The biggest risks include a severe share-price collapse, a Nasdaq listing deficiency, limited cash relative to losses, and an unproven commercial path.
• Explore Fractyl Health's Major News, Today's Price Move, Forecast, and Earnings on Tickeron's dedicated pages.
• Traders can also explore Trending AI Robots for AI-driven market strategies.

Understanding the $1.00 Target

Fractyl Health, Inc. (GUTS) is a clinical-stage metabolic therapeutics company developing the Revita duodenal mucosal resurfacing procedure and the Rejuva gene-therapy platform for obesity and type 2 diabetes. As a small, pre-revenue biotech, its sell-side coverage remains limited, and that coverage has been further affected by a 1-for-12 reverse stock split effective in early October 2026.

Before the split, published targets from firms including Morgan Stanley, HC Wainwright, Ladenburg Thalmann, and Canaccord Genuity ranged from roughly $2 to $8. Adjusted for the 1-for-12 split, those figures translate to approximately $0.17 to $0.67 — at or below the current share price. That makes them unusable as a forward-looking price forecast, so this analysis does not present an analyst consensus.

Instead, the $1.00 objective reflects a concrete, publicly discussed milestone: the $1.00 minimum bid price required to maintain Nasdaq listing compliance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Regaining and holding $1.00 is a realistic near-term benchmark that is roughly 23% above the latest price, but it is not a valuation target and should not be read as an analyst-derived price forecast.

Current Market Position and Path Toward the Target

Shares closed at $0.81 on November 10, 2026, with a market capitalization of roughly $11.9 million. A move to $1.00 would require a gain of about 23%, which is a substantial move for a stock that has already fallen sharply. The shares collapsed from about $4.00 in mid-October 2026 to below $1.00 within weeks, and the reported 52-week range of $0.81 to $29.34 spans both sides of the reverse split, making it misleading without that context.

The path toward $1.00 depends less on earnings momentum than on whether investors regain confidence that the company can fund its lead program, address its Nasdaq listing deficiency, and translate positive clinical data into a credible commercial story.

What Could Support a Move Toward the Target

Fractyl Health reported in mid-October 2026 that its REMAIN-1 pivotal cohort met its six-month co-primary endpoint, with Revita patients maintaining roughly 80% of their GLP-1 (glucagon-like peptide-1) induced weight loss after discontinuing therapy, versus about 67% for the sham arm (p=0.0023). The company has also announced a restructuring to sharpen its strategic focus on Revita, with about $2 million in severance-related charges.

An enormous and fast-growing obesity and type 2 diabetes market provides a large potential addressable opportunity, and the company reported roughly $47 million in cash on its most recent balance sheet. Small insider purchases over the past year are another modest sign of internal conviction.

What Could Prevent the Target From Being Reached

Despite meeting its endpoint, the stock sold off sharply, signaling investor skepticism about the magnitude of the treatment benefit, the durability of the effect, and the company's ability to commercialize a procedural therapy in a market dominated by injectable GLP-1 medicines. Fractyl Health also faces a Nasdaq continued-listing deficiency, and its net losses remain substantial relative to its cash position.

Additional risks include potential equity dilution to fund operations, execution risk around the restructuring, competition from large pharmaceutical companies, and the possibility that regulators or payers take a cautious view of an unproven device-and-procedure approach.

Technical Levels and Market Structure

The $1.00 level is significant for three reasons: it is a round-number psychological threshold, it is the Nasdaq minimum bid compliance level, and it was a trading zone the stock occupied as recently as late October 2026, when shares changed hands between roughly $1.00 and $1.55. A sustained move back above $1.00 would represent a meaningful recovery from the current area near the 52-week low, while failure to reclaim it would keep the listing-compliance overhang intact.

Time Horizon and What Investors Should Monitor

Analyst targets typically reflect a roughly 12-month horizon, but the $1.00 objective here is nearer-term and tied to Nasdaq's minimum bid price rule rather than a research time frame. Investors should watch the company's third-quarter earnings report scheduled for November 12, 2026, any commentary on cash runway and financing, Nasdaq compliance updates, additional REMAIN-1 data, the progress of the restructuring, and any refreshed or newly adjusted analyst ratings.

Using AI Daily Buy/Sell Signals for Monitoring

In my view, Tickeron's AI Daily Buy/Sell Signals provide a practical way to track volatile names like this one. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. I find it helpful for discovering opportunities, monitoring existing positions, and spotting shifting trends more efficiently than manual scanning allows, especially when filtering noise from meaningful technical changes in a stock like Fractyl Health.

Final Assessment

The $1.00 target for Fractyl Health is best understood as a listing-compliance and psychological milestone rather than a fundamental valuation. Reaching it requires a roughly 23% recovery from $0.81, which is achievable but far from assured given the company's steep decline, Nasdaq deficiency, and cash-burn profile. Positive REMAIN-1 data and the renewed focus on Revita provide genuine support, while investor skepticism, dilution risk, and an unproven commercial pathway remain the principal obstacles. The next earnings report, financing updates, and compliance developments will be the key signposts for whether the stock can stabilize above $1.00.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume